Hyundai Motor America Reports Record-Breaking March 2025 and Q1 Sales
March total sales increased 13%; sixth consecutive month of best-ever total sales
Best March ever total and retail; second biggest month in Hyundai history
Hyundai sets new Q1 total and retail sales record; Q1 total sales jump 10%
Best-ever Q1 total sales records; electrified up 38%; HEV jump 68%; EV increased 3%
Elantra N, Santa Fe, Tucson, IONIQ 5 and Palisade hit March records
FOUNTAIN VALLEY, Calif., April 1, 2025 /PRNewswire/ -- Hyundai Motor America reported record-breaking total March sales of 87,019 units, a 13% increase compared with March 2024. This was the best March in Hyundai's history, a record sixth consecutive month setting best-ever total sales. This was also the second-highest total sales month of all time. Total sales records in March were set for Elantra (+25%), Santa Fe (+25%), Tucson (+28%), IONIQ 5 (+17%) and Palisade (+20%). March total sales of hybrid electric vehicles jumped 72%, while total electrified sales grew by 38%.
"Hyundai achieved record Q1 total and retail sales, and our sixth consecutive month of best-ever total sales," said Randy Parker, CEO of Hyundai Motor North America. "With the opening of our Georgia Metaplant and a new $21 billion investment, we're expanding U.S. production, strengthening supply chains, and creating American jobs. Our commitment to innovation and meeting consumer demand remains strong, and we continue to localize production and enhance our supply chain to help manage market conditions."
March Retail HighlightsHyundai sold 79,019 retail units in March, a 15% year-over-year increase from March 2024. March retail sales were led by Tucson, Santa Fe, Elantra N, IONIQ 5 and Palisade. Hyundai electrified vehicle sales of 20,885 represented 26% of retail sales and a 44% year-over-year increase.
Q1 HighlightsIn the first quarter, Hyundai total sales were 203,554 units, a Q1 total sales record and an increase of 10% year-over-year. Q1 retail sales were 181,075, a 9% increase compared with Q1 2024 and a record for the first quarter. Hyundai also set new Q1 total and retail sales records for Santa Fe, Tucson, Palisade, and IONIQ 5. Electrified total sales were up 38% with hybrid-electric total sales jumping 68%. Hyundai electric vehicle total sales increased by 3%.
March Total Sales SummaryMar-25
Mar-24
% Chg
2025 YTD
2024 YTD
% Chg
Hyundai
87,019
76,920
+13 %
203,554
184,804
+10 %
March Product and Corporate Activities
Hyundai Motor Group Commits to U.S. Growth with $21 Billion Investment: Hyundai Motor Group announced a significant investment of $21 billion in the United States from 2025 to 2028. This commitment reflects the Group's strategic focus on expanding its manufacturing capabilities, advancing future technologies, and enhancing energy infrastructure in America. This latest U.S. investment builds on the Group's existing allocation of approximately $20.5 billion since entering the U.S. market in 1986.
Hyundai Motor Group Metaplant America Celebrates Grand Opening: Hyundai Motor Group Metaplant America hosted its Grand Opening celebration. The ceremony marks the completion of the largest economic development project in Georgia's history, just two and a half years after breaking ground.
Hyundai INSTER Named Top 3 Finalist at 2025 World Car Awards: Hyundai Motor Company's INSTER has been named a 'Top 3' finalist in the 2025 World Car Awards, marking the fourth consecutive year Hyundai has been recognized in this renowned global competition.
Five TOP SAFETY PICK+ Vehicle Designations by IIHS: Hyundai has been awarded five vehicles with TOP SAFETY PICK+ designations by the Insurance Institute of Highway Safety (IIHS). The 2025 IONIQ 5, IONIQ 6, Kona (ICE), Tucson/Tucson Hybrid and Santa Fe/Santa Fe Hybrid (built after Nov., 2024) have each received the highest-safety rating, TSP+ by IIHS.
Tucson Awarded 2025 Best Compact SUV for Families by U.S. News & World Report: The Hyundai Tucson has been named the 2025 Best Compact SUV for Families by U.S. News & World Report for a fourth-consecutive year. The publication's annual "Best Cars for Families" awards honor the cars, SUVs and minivans that deliver the best combination of reliability, safety, comfort, space, convenience and connectivity in their class.
SANTA FE Named 'Supreme Winner' at 2025 Women's Worldwide Car of the Year Awards: The all-new Hyundai SANTA FE has been named the 'Supreme Winner' at the 2025 Women's Worldwide Car of the Year Awards. The globally recognized WWCOTY 'Supreme Winner' title is awarded by the only all-female jury in the international automotive industry.
Hyundai Motor Group Launches 'Pleos' Software Brand, Unveiling New SDV Technologies and Collaborations: Hyundai Motor Group introduced its new mobility software brand 'Pleos' at its 'Pleos 25' developer conference in Seoul, also unveiling plans for collaboration with global partners to enhance in-vehicle app ecosystems.
Hyundai Leadership Honored as Reuters 2025 Trailblazing Women in Automotive: Three Hyundai executives, Claudia Márquez, Olabisi Boyle, and Kate Fabian have been named 2025 Trailblazing Women in Automotive by Reuters, a prestigious recognition honoring twenty outstanding global females who are leaders in the highly competitive automotive industry. This marks the first time three women from one company have received the honor in the same year, underscoring Hyundai's commitment to cultivating impactful leaders.
Hyundai Owners Gain Access to U.S. Tesla Superchargers With Complimentary NACS Adapters: U.S. owners of the current Hyundai KONA Electric, IONIQ Electric hatchback, IONIQ 5, and IONIQ 6 models equipped with a Combined Charging System (CCS) port will gain access to 20,000 Tesla Superchargers in the United States using a North American Charging Standard (NACS) adapter. Current owners of Hyundai EVs who bought their vehicles on or before January 31, 2025, will begin receiving emails with instructions on how to redeem their adapters starting the week of April 7.
Hyundai Expands Complimentary ChargePoint® Home Charger or $400 Charging Credit Offer: Hyundai announced the expansion of its complimentary home charger and charging credit offers to the 2025 IONIQ 6, 2024 IONIQ 6, and 2024 IONIQ 5 models.
Hyundai N Trophy Cup Set for North American Debut: The first leg of the 2025 Hyundai N Trophy Cup will be at the TC America (powered by Skip Barber) race, April 24 – 26, at the Circuit of the Americas near Austin, TX. Three additional TC America events are also a part of the Hyundai N Trophy Cup: Sebring, Barber Motorsports Park, and the TC America season finale at Indianapolis Motor Speedway.
Hyundai Continues Winning Streak with Victory at Sebring: Hyundai Motor America and Bryan Herta Autosport (BHA) continued their winning momentum in the 2025 IMSA Michelin Pilot Challenge (IMPC) season, securing victory at the Alan Jay Automotive 120 at Sebring International Raceway.
Model Total Sales
Vehicles
Mar-25
Mar-24
% Chg
2025 YTD
2024 YTD
% Chg
Elantra
14,461
11,528
+25 %
33,490
26,860
+25 %
Ioniq 5
3,919
3,361
+17 %
8,611
6,822
+26 %
Ioniq 6
1,435
1,984
-28 %
3,318
3,646
-9 %
Kona
7,024
9,453
-26 %
17,018
23,054
-26 %
Nexo
0
17
-100 %
0
51
-100 %
Palisade
11,742
9,785
+20 %
26,235
25,255
+4 %
Santa Cruz
2,924
3,362
-13 %
6,648
8,417
-21 %
Santa Fe
13,543
10,834
+25 %
31,401
26,094
+20 %
Sonata
5,706
5,664
+1 %
15,797
13,164
+20 %
Tucson
23,631
18,394
+28 %
54,973
45,509
+21 %
Venue
2,634
2,538
+4 %
6,063
5,932
+2 %
Hyundai Motor AmericaHyundai Motor America offers U.S. consumers a technology-rich lineup of cars, SUVs, and electrified vehicles, while supporting Hyundai Motor Company's Progress for Humanity vision. Hyundai has significant operations in the U.S., including its North American headquarters in California, the Hyundai Motor Manufacturing Alabama assembly plant, the all-new Hyundai Motor Group Metaplant America, and several cutting-edge R&D facilities. These operations, combined with those of Hyundai's 835 independent dealers, contribute $20.1 billion annually and 190,000 jobs to the U.S. economy, according to a published economic impact report. For more information, visit www.hyundainews.com.
Hyundai Motor America on Twitter | YouTube | Facebook | Instagram | LinkedIn | TikTok
View original content to download multimedia:https://www.prnewswire.com/news-releases/hyundai-motor-america-reports-record-breaking-march-2025-and-q1-sales-302416683.html
SOURCE Hyundai Motor America
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
39 minutes ago
- Yahoo
Engineering the Perfect Shower Squeegee: The Story Behind dancemoon JustHang Squeegee
NEW YORK, June 7, 2025 /PRNewswire/ -- dancemoon, the trailblazer in home cleaning innovation, proudly introduced its first-ever bathroom cleaning tool: the JustHang Squeegee. Designed for effortless use and stylish storage, the product officially launched worldwide on June 3 via dancemoon's website and Amazon, debuting at a special launch price of $19.99. It has been well-received on social media for its outstanding performance and uniquely innovative built-in hook, and has continued to gain traction on Amazon and the official website since its initial launch. What sets the JustHang Squeegee apart is the thoughtful design, inspired by the simple and universal natural habit of hanging things up after use. Through rounds of real-life testing and countless small tweaks, the dancemoon team turned this everyday habit into a clean, minimalist solution that blends form and function. And behind this seemingly simple tool is a deliberate design process worth sharing. How It's Made: Integrated Molded Structure: The built-in hook of JustHang Squeegee isn't a traditional after-assembly attachment. Instead, it is molded by one-piece injection molding. This process reduces breakage risk at joints, maintains minimalist lines and structural stability, prevents dirt buildup and avoids discoloration over time. The handle uses glass fiber reinforced PA66 and the scraper blade is made of hardened 45 steel, offering excellent strength and heat resistance, enabling JustHang Squeegee to withstand up to 75kg pressure without breaking. Size and Angle Validation: Based on user habit research, dancemoon designers analyzed common hanging points and user behaviors in the bathroom. Through multiple prototype tests and hanging simulations, the size and angle of the built-in hook were finely adjusted to ensure that it can be firmly fixed in places such as towel bars, glass doors and countertops, and perfectly fit the user's natural "use and hang" action. Premium Flexible Silicone: Made from high-elasticity 50 Shore A silicone, this material offers an ideal balance of flexibility and structural strength. After extensive durability testing, the dancemoon design team selected this specific hardness for its outstanding performance in wet and slippery environments, resisting deformation and cracking even with prolonged use. The result is a smoother, more efficient water-wiping experience and a significantly longer lifespan compared to traditional squeegees. Why JustHang Squeegee? Convenience: Effortless to hang anywhere even with wet hands. Versatility: Designed to fit seamlessly into various home settings, offering clean, clutter-free storage. Durability: One-piece molded construction minimizes breakage and lasts longer than traditional scrapers. To place an order, please visit dancemoon's Amazon store and Shopify. Or follow dancemoon on social media to stay updated with the latest campaigns for the new product: Instagram: Facebook: YouTube: About dancemoon Driven by a passion for innovative design, dancemoon infuses the beauty and emotion of the moon into each product. Beyond offering household tools, dancemoon combines innovation with minimalist design to create products that make household tasks simple and no longer a burden but an enjoyable part of life. With a vision to become the leading brand of minimalist lifestyle, dancemoon is committed to blending minimalism with household tools, bringing bliss into your daily life. CONTACT: info@ View original content to download multimedia: SOURCE dancemoon
Yahoo
10 hours ago
- Yahoo
Nucleus Genomics Launches Nucleus Embryo, Genetic Optimization Software Alongside Partnership with Genomic Prediction
Parents pursuing IVF now have a new level of choice to empower their family planning NEW YORK, June 4, 2025 /PRNewswire/ -- With U.S. birthrates plummeting and IVF on the rise, Nucleus Genomics today launched Nucleus Embryo, the first genetic optimization software that lets parents see and understand a complete genetic profile to select an embryo. "Before there's a heartbeat, there's DNA," said Kian Sadeghi, founder and CEO of Nucleus. "One file containing DNA and genetic markers can tell you more about your baby's future than any other test a doctor could possibly run at this stage. Most clinics stop at whether an embryo will develop. For many parents, that's not enough. Patients have long asked for more transparency from clinics, and Nucleus Embryo is an important step toward complete data ownership for parents planning their families." The software enables parents to analyze and compare up to 20 embryos across over 900 hereditary conditions and 40 additional analyses beyond basic viability, spanning cancers, chronic conditions, appearance, cognitive ability, mental health, and more. To widen access to the software, Nucleus will partner with Genomic Prediction, the first company to offer genome-wide screening on embryos. The partnership sets a new standard in genetic medicine, continuing Genomic Prediction's decade-long history of giving hopeful parents the best possible chance of implanting healthy embryos. The company's analyses focus on hereditary conditions, acting as the first line of defense against chronic and rare diseases. "As an organization, we are committed to supporting patients' rights to their DNA and any information that can aid in their family-building journey," said Kelly Ketterson, CEO of Genomic Prediction. "We have a legacy of innovation aimed at providing patients with access to the best scientific resources. Our partnership with Nucleus opens access to information our patients have requested and allows us to uphold our commitment to this legacy." Nucleus' partnership with Genomic Prediction reflects a growing shift in how parents think about genetics as a tool to give children the best possible start in life. A wide-ranging study of Americans found the majority accepted the use of genetic technology to choose embryos based on health and personality traits. Four in 10 parents would use genetic optimization as another tool to understand their future child's cognitive abilities. Most women undergo three to six IVF cycles before successfully having a baby, with each cycle costing up to $25,000. Many embryos are unviable within days of being fertilized, leaving parents with few to choose from. Facing high stakes, clinicians often recommend genetic testing to optimize a couple's chances of a healthy pregnancy. But these tests typically stop at a select number of hereditary conditions and chromosome count. Now, advanced genetic analysis from Nucleus gives parents a new window into the health and well-being of their future child. Nucleus Embryo provides a comprehensive genetic profile for each embryo, encompassing hereditary genetic diseases, like cystic fibrosis and hemochromatosis, alongside genetic measures of cognitive ability, mental health, and risk for chronic diseases. Wide access to genetic insights for embryos can also help extend lifespan from the earliest stages of life. While more than half of all deaths annually in the U.S. are attributed to chronic, age-related conditions — such as Alzheimer's disease, diabetes, cancer, and heart disease — research shows embryonic selection can materially help reduce disease risk for these conditions. "We celebrate health optimization and the pursuit of longevity in every other part of life via our focus on training, supplements, and sleep," Sadeghi said. "We all know health isn't just the absence of disease. It's the ability to understand our bodies and genetic makeup to reach our full potential. Now we can apply this principle to life's inception." About Nucleus Genomics Nucleus builds software for generational health. Inspired by the loss of his cousin who died of a rare — yet preventable — genetic disease, Nucleus founder and Thiel Fellow Kian Sadeghi left an Ivy League university to build a product that could have saved her life. Our advanced DNA health test and analysis takes the guesswork out of your health, whether it's perfecting your protocols, knowing your risk for cancer, or planning for a healthy family. Follow us on social media @nucleusgenomics. About Genomic Prediction Genomic Prediction, Inc. is the frontrunner in advanced embryo screening. Our proprietary LifeView platform is state-of-the-art technology that assesses embryos for genetic health aimed at improved IVF outcomes. The LifeView Embryo Health Score Test (EHS) offers insight into the likelihood of developing conditions driven by multiple genes. It tests for significant health issues, including cardiovascular disease, diabetes mellitus, certain cancers, and mental health conditions. The EHS results are derived from the same embryo sample used in the following PGT tests: PGT-A: Identifies chromosome abnormalities in embryos. PGT-A+: Pinpoints the origin (paternal, maternal, or embryonic) of chromosome abnormalities. PGT-M: Decreases the chances of passing on monogenic (single-gene) conditions. PGT-SR: Detects chromosome abnormalities and structural imbalances, providing clarity between normal and balanced chromosomes. View original content to download multimedia: SOURCE Nucleus
Yahoo
12 hours ago
- Yahoo
The British Medical Journal Publishes Study Results on Sacituzumab Tirumotecan for Previously Treated EGFR-Mutant Advanced NSCLC
CHENGDU, China, June 6, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech", today announced that results from its registrational study (OptiTROP-Lung03) evaluating sacituzumab tirumotecan (sac-TMT) versus docetaxel in patients with previously treated advanced EGFR-mutant non-small cell lung cancer (NSCLC) have been published in The British Medical Journal (impact factor: 93.6). These data were also presented as an oral presentation in the Lung Cancer—Non–Small Cell Metastatic session (Abstract #8507) at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. Based on the encouraging data from this study, sac-TMT was approved for marketing by the National Medical Products Administration (NMPA) for the treatment of adult patients with epidermal growth factor receptor (EGFR) mutant-positive locally advanced or metastatic non-squamous NSCLC following progression on EGFR-tyrosine kinase inhibitor (TKI) therapy and platinum-based chemotherapy in March 2025. This marks the first global approval of a TROP2 ADC for a lung cancer indication. The published results are based on OptiTROP-Lung03, an open-label, randomized, multicenter registrational study evaluating the efficacy and safety profile of sac-TMT monotherapy versus docetaxel for the treatment of patients with locally advanced or metastatic EGFR-mutant NSCLC who have failed after treatment with an EGFR-TKI and platinum-based chemotherapy. A total of 137 patients with advanced EGFR-mutant NSCLC who had progressed after EGFR-TKI and platinum-based chemotherapy were randomized (2:1) to receive sac-TMT (5 mg/kg once every 2 weeks) or docetaxel (75 mg/m2 once every 3 weeks) until disease progression, intolerable toxicity or other reason for discontinuation, with a median follow-up time of 12.2 months (Data cutoff date: December 31, 2024). Sac-TMT achieved statistically significant and clinically meaningful outcomes compared to docetaxel: Confirmed objective response rate (ORR) (As assessed by blinded independent review committee (BIRC): 45% (95% CI, 35-56) vs 16% (95% CI, 7-30). Median progression-free survival (PFS) (As assessed by BIRC: 6.9 months [sac-TMT; 95% CI, 5.4-8.2] vs 2.8 months [docetaxel; 95% CI, 1.6-4.1], hazard ratio (HR)= 0.30 [range, 0.20 -0.46], one-sided p<0.0001; as assessed by investigator (INV): 7.9 months [sac-TMT; 95% CI, 6.2-9.5] vs 2.8 months [docetaxel; 95% CI, 1.5-3.8], HR=0.23 [95% CI, 0.15-0.36], one-sided p<0.0001). With 36.4% of patients in docetaxel group crossing over to receive sac-TMT, median overall survival (OS) was not reached (NR) for both groups (HR=0.49; 95% CI, 0.27-0.88; one-sided p=0.007). The median OS analysed by pre-specified rank-preserving structural failure time (RPSFT) model adjusted for crossover was 9.3 months for docetaxel and NR for sac-TMT (HR=0.36; 95% CI, 0.20-0.66). Efficacy benefit favored patients with sac-TMT over docetaxel across all pre-specified subgroups, including prior EGFR-TKI therapy, brain metastases, EGFR mutation type, etc. Grade ≥ 3 treatment-related adverse events (TRAEs) occurred in 56.0% of patients in sac-TMT group vs 71.7% in docetaxel group. The results demonstrated that sac-TMT monotherapy achieved statistically significant and clinically meaningful improvements in objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) compared to docetaxel, with a manageable safety profile. Sac-TMT is being extensively studied in the NSCLC field. Covering treatment settings from later-line therapy to early-stage postoperative adjuvant therapy, including both monotherapy and combination regimens. Currently, five company-led registrational clinical studies for sac-TMT in NSCLC are underway in China. Meanwhile, Merck Sharp & Dohme（the tradename of Merck & Co., Inc., Rahway, NJ, USA）is also conducting five global Phase III clinical trials of sac-TMT for NSCLC in regions where it has exclusive rights. Professor Li Zhang, National Lead Principal Investigator, Medical Oncologist and Deputy Director of the Lung Cancer Research Centre at Sun Yat-Sen University, stated: "EGFR mutation is the most common driver alteration in NSCLC. The prevalence of EGFR mutations reaches 28.2% among NSCLC patients in China. Although third-generation EGFR-TKIs have become the standard of care for advanced EGFR-mutant NSCLC and may significantly improve PFS, acquired resistance remains inevitable. Combining EGFR-TKIs with chemotherapy can offer additional survival benefits to some patients, but this approach is limited by safety concerns and may compromise future treatment options, posing significant clinical challenges. The publication of the OptiTROP-Lung03 study in the British Medical Journal marks a major milestone—not only highlighting international recognition of this study outcomes in lung cancer, but also demonstrating the global competitiveness of sac-TMT as a novel TROP2 ADC." Dr. Michael Ge, CEO of Kelun-Biotech, commented: "We are thrilled to see the OptiTROP-Lung03 study published in a top-tier journal. Currently, EGFR-TKIs and chemotherapy remain the standard of care for patients with EGFR-mutant advanced NSCLC, but the challenge of increasing efficacy with manageable tolerability. The results from OptiTROP-Lung03 highlight significant survival benefits with manageable safety profile and suggest that sac-TMT could emerge as a new standard of care for this population. We remain committed to working with our partners to establish sac-TMT as a new standard of care for this patient population and improve outcomes for lung cancer patients worldwide." Registrational Study Led by Kelun-Biotech OptiTROP-Lung03: Sac-TMT monotherapy versus docetaxel for locally advanced or metastatic EGFR-mutant NSCLC after treatment failure with EGFR-TKI and platinum-containing chemotherapy； OptiTROP-Lung04: Sac-TMT monotherapy versus pemetrexed in combination with platinum for locally advanced or metastatic non-squamous NSCLC with EGFR mutations that have failed EGFR-TKI therapy； OptiTROP-Lung05: Sac-TMT combined with pembrolizumab versus chemotherapy combined with pembrolizumab for first-line treatment of PD-L1-positive locally advanced or metastatic NSCLC; OptiTROP-Lung06: Sac-TMT combined with pembrolizumab versus chemotherapy combined with pembrolizumab for the first-line treatment of PD-L1-negative locally advanced or metastatic non-squamous NSCLC; OptiTROP-Lung07: First-line treatment of locally advanced or metastatic NSCLC with EGFR mutations by sac-TMT in combination with ositinib. Registrational Study Led by MSD NSCLC not achieving a pCR after neoadjuvant therapy followed by surgery. NSCLC expressing PD-L1 >50% pre-treated NSCLC with EGFR mutations or other genomic alterations EGFR-mutated, advanced non-squ NSCLC progressed on prior EGFR-TK metastatic sg NSCLC About sac-TMT Sac-TMT, a core product of the Company, is a novel human TROP2 ADC in which the Company has proprietary intellectual property rights, targeting advanced solid tumors such as NSCLC, BC, gastric cancer (GC), gynecological tumors, among others. Sac-TMT is developed with a novel linker to conjugate the payload, a belotecan-derivative topoisomerase I inhibitor with a drug-to-antibody-ratio (DAR) of 7.4. Sac-TMT specifically recognizes TROP2 on the surface of tumor cells by recombinant anti-TROP2 humanized monoclonal antibodies, which is then endocytosed by tumor cells and releases KL610023 intracellularly. KL610023, as a topoisomerase I inhibitor, induces DNA damage to tumor cells, which in turn leads to cell-cycle arrest and apoptosis. In addition, it also releases KL610023 in the tumor microenvironment. Given that KL610023 is membrane permeable, it can enable a bystander effect, or in other words kill adjacent tumor cells. In May 2022, the Company licensed the exclusive rights to MSD (the tradename of Merck & Co., Inc., Rahway, NJ, USA) to develop, use, manufacture and commercialize sac-TMT in all territories outside of Greater China (includes Mainland China, Hong Kong, Macao, and Taiwan). To date, two indications for sac-TMT have been approved and marketed in China for the treatment of adult patients with unresectable locally advanced or metastatic TNBC who have received at least two prior systemic therapies (at least one of them for advanced or metastatic setting) based on the OptiTROP-Breast01 study and EGFR mutation-positive locally advanced or metastatic non-squamous NSCLC following progression on EGFR-TKI therapy and platinum-based chemotherapy based on the OptiTROP-Lung03 study. Sac-TMT became the first domestic ADC with global intellectual property rights to be fully approved for marketing. It is also the world's first TROP2 ADC to be approved for marketing in a lung cancer indication. In addition, two new indication applications for sac-TMT for the treatment of adult patients with EGFR-mutant locally advanced or metastatic NSCLC who progressed after treatment with EGFR-TKI therapy and with unresectable locally advanced, metastatic hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) BC who have received prior endocrine therapy and other systemic treatments in the advanced or metastatic setting were accepted by the National Medical Products Administration (NMPA), and were reviewed via the priority review and approval process. As of today, the Company has initiated 8 registrational clinical studies in China. MSD has initiated 14 ongoing Phase 3 global clinical studies of sac-TMT as a monotherapy or with pembrolizumab or other agents for several types of cancer. These studies are sponsored and led by MSD. About Kelun-Biotech Kelun-Biotech（ a holding subsidiary of Kelun Pharmaceutical ( which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. The company focuses on major disease areas such as solid tumors, autoimmune, inflammatory, and metabolic diseases, and in establishing a globalized drug development and industrialization platform to address the unmet medical needs in China and the rest of world. The Company is committed to becoming a leading global enterprise in the field of innovative drugs. At present, the Company has more than 30 ongoing key innovative drug projects, of which 3 projects have been approved for marketing, 1 project is in the NDA stage, and more than 10 projects are in the clinical stage. The company has established one of the world's leading proprietary ADC platforms, OptiDC™, and has 1 ADC project approved for marketing, 1 ADC project in NDA stage, and multiple ADC and novel coupled drug products in clinical or preclinical research stage. For more information, please visit Media: klbio_pr@ View original content to download multimedia: SOURCE Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
